KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 50 filers reported holding KALVISTA PHARMACEUTICALS INC in Q3 2018. The put-call ratio across all filers is - and the average weighting 1.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $28,453,000 | +11.4% | 1,930,322 | 0.0% | 0.62% | +38.0% |
Q4 2021 | $25,538,000 | -24.2% | 1,930,322 | 0.0% | 0.45% | -3.6% |
Q3 2021 | $33,684,000 | -27.2% | 1,930,322 | 0.0% | 0.47% | -37.1% |
Q2 2021 | $46,251,000 | +414.4% | 1,930,322 | +451.5% | 0.74% | +445.6% |
Q1 2021 | $8,992,000 | -78.2% | 350,000 | -75.7% | 0.14% | -92.4% |
Q1 2019 | $41,243,000 | +44.9% | 1,441,070 | 0.0% | 1.78% | +7.3% |
Q4 2018 | $28,461,000 | -10.7% | 1,441,070 | 0.0% | 1.66% | -2.7% |
Q3 2018 | $31,862,000 | +172.3% | 1,441,070 | 0.0% | 1.70% | +124.1% |
Q2 2018 | $11,701,000 | -14.3% | 1,441,070 | 0.0% | 0.76% | -27.4% |
Q1 2018 | $13,661,000 | -2.8% | 1,441,070 | 0.0% | 1.05% | -11.0% |
Q4 2017 | $14,050,000 | +223.0% | 1,441,070 | +143.8% | 1.18% | +199.2% |
Q3 2017 | $4,350,000 | 0.0% | 591,070 | 0.0% | 0.39% | -21.2% |
Q2 2017 | $4,350,000 | -5.8% | 591,070 | 0.0% | 0.50% | -11.8% |
Q1 2017 | $4,616,000 | +10.5% | 591,070 | 0.0% | 0.57% | -4.4% |
Q4 2016 | $4,179,000 | – | 591,070 | – | 0.59% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SV Health Investors, LLC | 1,719,576 | $25,679,000 | 12.37% |
Vivo Capital, LLC | 1,618,296 | $30,731,000 | 1.37% |
Opaleye Management Inc. | 470,203 | $8,929,000 | 1.17% |
INTERWEST VENTURE MANAGEMENT CO | 388,766 | $7,383,000 | 0.92% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 177,433 | $3,369,000 | 0.92% |
Ikarian Capital, LLC | 1,063,961 | $20,204,000 | 0.89% |
Ghost Tree Capital, LLC | 200,000 | $3,798,000 | 0.85% |
Logos Global Management LP | 490,000 | $9,305,000 | 0.80% |
Eventide Asset Management | 1,680,000 | $31,903,000 | 0.49% |
Affinity Asset Advisors, LLC | 45,000 | $855,000 | 0.45% |